CAS 213252-19-8|KRP-297

Introduction：Basic information about CAS 213252-19-8|KRP-297, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. KRP-297 BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	KRP-297
CAS Number	213252-19-8	Molecular Weight	438.42000
Density	1.395g/cm3	Boiling Point	605.4ºC at 760 mmHg
Molecular Formula	C₂₀H₁₇F₃N₂O₄S	Melting Point	/
MSDS	/	Flash Point	319.9ºC

Names

Name	5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
Synonym	More Synonyms

KRP-297 BiologicalActivity

Description	KRP-297 is a PPARα and PPARγ agonist potentially for the treatment of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
Related Catalog	Signaling Pathways >>Cell Cycle/DNA Damage >>PPARResearch Areas >>Metabolic Disease
References	[1]. Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes. 1998;47(12):1841-1847. [2]. Kochansky CJ, Rippley RK, Yan KX, et al. Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans. Drug Metab Dispos. 2006;34(9):1457-1461.

Description

KRP-297 is a PPARα and PPARγ agonist potentially for the treatment of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.

Related Catalog

Signaling Pathways >>Cell Cycle/DNA Damage >>PPARResearch Areas >>Metabolic Disease

References

[1]. Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes. 1998;47(12):1841-1847.

[2]. Kochansky CJ, Rippley RK, Yan KX, et al. Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans. Drug Metab Dispos. 2006;34(9):1457-1461.

Chemical & Physical Properties

Density	1.395g/cm3
Boiling Point	605.4ºC at 760 mmHg
Molecular Formula	C₂₀H₁₇F₃N₂O₄S
Molecular Weight	438.42000
Flash Point	319.9ºC
Exact Mass	438.08600
PSA	116.78000
LogP	4.38880
Vapour Pressure	1.32E-14mmHg at 25°C
Index of Refraction	1.58
InChIKey	NFFXEUUOMTXWCX-UHFFFAOYSA-N
SMILES	COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1

Synonyms

[3H]-MK-0767

N-(4-trifluoromethylbenzyl)-5-(2,4-dioxothiazolidin-5-yl)methyl-2-methoxybenzamide

[14C]-MK-0767

5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide

5-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxy-N-[4-(trifluoromethyl)benzyl]benzamide

MK 767

MK-0767

5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide

KRP 297

Recommended......